GlassScriptPhysician profile
Megan E Lanigan
NPI 1699144741
$5,881.61
in general payments reported to CMS, 2019-2025
10 companies · $3,315 in 2025
The $3,315 reported for 2025 was more than what 99% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
See the full distribution for Women's Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $180 · 2022: $284 · 2023: $389 · 2024: $1,714 · 2025: $3,315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,800 · Food and Beverage: $1,539 · Travel and Lodging: $1,079.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,800.00 |
| Food and Beverage | $1,538.67 |
| Travel and Lodging | $1,078.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,249.13 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $434.25 | 2022-2025 | Keytruda, Lynparza |
| Glaxosmithkline, LLC. | $409.23 | 2022-2025 | Jemperli, Zejula |
| Eisai INC. | $223.01 | 2024-2025 | |
| Tactile Systems Technology INC | $162.30 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $123.61 | 2022-2023 | |
| Genmab U.S., INC. | $101.70 | 2023 | Tivdak |
| Seagen INC. | $91.21 | 2022 | |
| Immunogen, INC. | $69.95 | 2023 | Elahere |
| Clovis Oncology, INC. | $17.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Lanigan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.